OakChart

Aura Biosciences Inc

AURAHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 8:25 AM ET

7.61-0.04 (-0.52%)
2026-11-11 14:31 CET
Market cap
793.34 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-136.95 USD m
Free cash flow, TTM
-109.68 USD m
EPS diluted, TTM
-1.67
P/E
-
Compare

Price

AURA against its 20, 50 and 200-day averages
2050200beatmiss
6.007.008.001.9M3.8MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26AURAclose 7.6120-day 6.5350-day 6.56200-day 6.777.61

20.2% under 9.54 on 5 May 2026. Last 15 sessions, 35.1% high to low

Profile

AURA
52-week range, 60% of the way up
4.739.53

Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.

IndexRUT
Employees113
IPOOct 29, 2021
Beta0.41
ATR, 14d0.37
Rel volume0.00
Short float25.10%
Insider own59.80%
Inst own64.36%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap792.01M
Enterprise Value510.95M
Income-136.95M
Sales0.00M
Book/sh2.77
Cash/sh2.86
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees113
IPOOct 29, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.75
P/C2.66
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio14.21
Current Ratio14.21
Debt/Eq0.06
LT Debt/Eq0.04
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.67
EPS next Y-1.25
EPS next Q-0.30
EPS this Y14.09%
EPS next Y17.33%
EPS next 5Y14.24%
EPS past 3/5Y3.57% -11.28%
Sales past 3/5Y- -
EPS Y/Y TTM13.33%
Sales Y/Y TTM-
EPS Q/Q27.15%
Sales Q/Q-
EarningsNov 09 BMO
EPS/Sales Surpr.21.22% -

Ownership

Insider Own59.80%
Insider Trans-10.06%
Inst Own64.36%
Inst Trans33.19%
ROA-53.53%
ROE-61.67%
ROIC-45.61%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2016.57%
SMA5016.08%
SMA20012.34%
Trades-

Technical

Shs Outstand103.95M
Shs Float41.69M
Short Float25.10%
Short Ratio11.53
Short Interest10.46M
52W High9.53 -20.19%
52W Low4.73 60.89%
Volatility8.71% 5.58%
ATR (14)0.37
RSI (14)67.82
Beta0.41
Rel Volume0.00
Avg Volume907.49K
Volume18

Performance

Perf Week14.44%
Perf Month21.37%
Perf Quarter-0.52%
Perf Half Y-5.11%
Perf YTD39.63%
Perf Year34.45%
Perf 3Y-1.04%
Perf 5Y-55.88%
Perf 10Y-
Recom1.00
Target Price16.60
Prev Close7.65
Price7.61
Change %-0.52%

Analyst ratings

latest 6 of 6
DateActionAnalystRating changeTargetImplied
Nov 26, 2025ResumedEEvercore ISIOutperform$13+70.8%
May 28, 2025ResumedHH.C. WainwrightBuy$22+189.1%
Jul 25, 2024InitiatedHH.C. WainwrightBuy$21+176.0%
Jul 27, 2023InitiatedBScotiabankSector Outperform
Apr 17, 2023ResumedBBTIG ResearchBuy$38+399.3%
Jul 19, 2022InitiatedJJMP SecuritiesMkt Outperform$26+241.7%

Peers

Mkt cap
TickerCompanyMkt cap
IDYAIdeaya Biosciences Inc3.07B
IMCRImmunocore Holdings plc ADR1.67B
CGONCg Oncology Inc6.65B
DCTHDelcath Systems Inc695.76M
URGNUroGen Pharma Ltd1.25B
CADLCandel Therapeutics Inc723.10M
OCULOcular Therapeutix Inc1.54B
REPLReplimune Group Inc2.24B
EYPTEyePoint Inc35.18M
KODKodiak Sciences Inc6.79B

Insider trading

latest 14 of 21
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Gibney AnthonyOfficerJun 16 '26Proposed Sale6.4212,82482,330Jun 16 04:30 PM
Gibney Anthony SSee RemarksJun 16 '26Sale6.4212,82482,330265,354Jun 16 04:30 PM
Matrix Capital Management Comp10% OwnerMay 07 '26Sale5.646,922,87039,044,9870May 11 04:16 PM
Kilroy ConorOfficerApr 16 '26Proposed Sale7.0211,73882,402Apr 16 06:50 PM
Kilroy ConorSee RemarksApr 16 '26Sale7.0211,73882,401217,835Apr 16 06:49 PM
Kilroy ConorOfficerFeb 17 '26Proposed Sale5.0512,07961,037Feb 17 07:51 PM
Plavsic MarkOfficerFeb 17 '26Proposed Sale5.0515,89080,271Feb 17 07:50 PM
Hopkins Janet JillOfficerFeb 17 '26Proposed Sale5.0620,401103,231Feb 17 07:50 PM
Elazzouzi AmyOfficerFeb 17 '26Proposed Sale5.068,54943,261Feb 17 07:50 PM
de los Pinos ElisabetOfficerFeb 17 '26Proposed Sale5.0647,648241,063Feb 17 07:49 PM
Kilroy ConorSee RemarksFeb 17 '26Sale5.0512,07960,999167,234Feb 17 07:48 PM
Plavsic MarkChief Technology OfficerFeb 17 '26Sale5.0515,89080,244181,397Feb 17 07:47 PM
Hopkins Janet JillChief Medical OfficerFeb 17 '26Sale5.0620,401103,229232,284Feb 17 07:47 PM
Elazzouzi AmySenior Vice President, FinanceFeb 17 '26Sale5.068,54943,25875,532Feb 17 07:47 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 689.41B
IWMiShares Russell 2000 Index FundAUM: 78.30B
XBIState Street SPDR S&P Biotech ETFAUM: 10.53B
VXFVanguard Extended Market Index ETFAUM: 30.61B
IBBiShares Biotechnology ETFAUM: 11.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.20B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.85B
DFASU.S. Small Cap Portfolio-ETF Class SharesAUM: 15.57B
VTWOVanguard Russell 2000 Index ETFAUM: 16.97B
VHTVanguard Health Care ETFAUM: 21.40B

News

latest 14 of 206
  • Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire) +16.77%
  • Aura Biosciences to Participate in Upcoming Investor Conference (GlobeNewswire) +6.57%
  • Aura Biosciences to Participate in Upcoming Investor Conference (GlobeNewswire)
  • Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights (GlobeNewswire)
  • Loading…
  • Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors (GlobeNewswire)
  • Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma (GlobeNewswire)
  • Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Aura Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights (GlobeNewswire)
  • Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +6.59% -6.85%
  • Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants (GlobeNewswire) +19.12%
  • Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-09-0.290-0.368-0.2900.000.004
2026Q22026-08-11-0.480-0.375-0.4810.000.004
2026Q12026-05-11-0.500-0.398-0.4990.000.004
2025Q42026-03-30-0.340-0.428-0.4020.000.004
2025Q32025-11-13-0.400-0.464-0.3960.000.005
2025Q22025-08-13-0.470-0.478-0.4660.000.005
2025Q12025-05-15-0.550-0.491-0.5480.000.005
2024Q42025-03-24-0.520-0.444-0.5180.000.006
2024Q32024-11-12-0.420-0.441-0.4240.000.007
2024Q22024-08-08-0.410-0.450-0.4100.000.006
2024Q12024-05-09-0.400-0.486-0.3990.000.005
2023Q42024-03-27-0.510-0.421-0.4980.000.006
2023Q32023-11-09-0.480-0.521-0.4850.000.005
2023Q22023-08-09-0.480-0.490-0.4830.000.005
2023Q12023-05-11-0.460-0.540-0.4620.000.003
2022Q42023-03-15-0.520-0.506-0.5200.000.005

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-8.950-5.890-1.5810.000.00
2022FY-1.960-1.944-1.9630.000.00
2023FY-1.930-1.842-1.9290.000.00
2024FY-1.750-1.676-1.7510.000.00
2025FY-1.760-1.959-1.7600.000.00
2026FY--1.512--0.00
2027FY--1.250--4.93
2028FY--1.110--16.04
2029FY--0.420--136.61
2030FY-0.130--222.55

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-093000.000.000.00
2026Q4S2026-08-113000.000.000.00
2026Q4S2026-05-123000.000.000.00
2026Q4S2026-04-283000.000.000.00
2026Q4S2026-03-302000.000.000.00
2026Q4S2025-11-132000.000.000.00
2026Q4S2025-11-111000.000.000.00
2026Q4S2025-11-101000.000.000.00
2026Q4S2025-11-091000.000.000.00
2026Q4R2026-11-09110-0.26-0.26-0.26
2026Q4R2026-10-25100-0.27-0.27-0.27
2026Q4R2026-08-11110-0.27-0.27-0.27
2026Q4R2026-07-26100-0.33-0.33-0.33
2026Q4R2026-05-12110-0.33-0.33-0.33

Estimate history

EPS, annual-1.035-1.031-1.581-1.963-1.929-1.751-1.76-1.6711
Period2019202020212022202320242025TTM
EPS, quarterly-0.424-0.518-0.548-0.466-0.396-0.402-0.499-0.481-0.289
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00000000
Period2019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual29.2229.2229.21237.77249.35149.99863.588103.951
Period2019202020212022202320242025MRQ
Shares, quarterly49.77949.99850.22562.07162.98663.58864.15103.48103.951
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A1.151.131.221.291.180.830.830.51
Gross Profit-1.15-1.13-1.22-1.29-1.18-0.83-0.83-0.51
Selling, General and Administrative Excl. Other144.09111.6694.8983.7059.1234.4121.3823.63
Research and Development105.3590.3073.3063.9441.0624.3317.2119.11
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-145.23-112.79-96.12-84.99-60.30-35.25-22.21-24.14
Interest Expense0.000.00----0.000.01
Unusual Expense0.000.000.000.000.000.01-0.000.04
Net Income Before Taxes-136.85-106.08-86.81-76.27-58.76-35.25-22.21-24.20
Income Taxes0.090.110.110.140.000.000.000.00
Consolidated Net Income-136.95-106.19-86.92-76.41-58.76-35.25-22.21-24.20
Net Income From Continuing Operations-136.95-106.19-86.92-76.41-58.76-35.25-22.21-24.20
Net Income-136.95-106.19-86.92-76.41-58.76-46.19-30.13-30.23
EPS (Recurring)-1.23-1.76-1.75-1.93-1.96-1.58-1.03-1.03
EPS (Basic, Before Extraordinaries)-1.67-1.76-1.75-1.93-1.96-1.58-1.03-1.03
EPS (Diluted)-1.67-1.76-1.75-1.93-1.96-1.58-1.03-1.03
EBITDA-144.09-111.66-94.89-83.70-59.12-34.41-21.38-23.63
Non-Operating Income (Expense)8.386.719.318.721.530.010.00-0.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense19.2711.319.266.936.412.310.740.51
Shares Outstanding103.9563.5950.0049.3537.7729.2129.2229.22
Market Capitalization793.34793.34410.60338.60307.47482.39472.17-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.300.300.270.270.300.300.290.29
Gross Profit-0.30-0.30-0.27-0.27-0.30-0.30-0.29-0.29
Selling, General and Administrative Excl. Other34.7647.7734.5926.9627.6128.3128.7427.52
Research and Development24.7430.7527.9621.9022.1822.8823.3422.33
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-35.06-48.07-34.87-27.24-27.91-28.61-29.04-27.81
Interest Expense0.000.000.000.00----
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-32.03-45.61-33.67-25.54-26.10-26.97-27.46-25.81
Income Taxes0.040.030.010.010.030.050.020.02
Consolidated Net Income-32.07-45.64-33.69-25.56-26.13-27.02-27.48-25.83
Net Income From Continuing Operations-32.07-45.64-33.69-25.56-26.13-27.02-27.48-25.83
Net Income-32.07-45.64-33.69-25.56-26.13-27.02-27.48-25.83
EPS (Recurring)-0.29-0.48-0.50-0.40-0.40-0.47-0.55-0.52
EPS (Basic, Before Extraordinaries)-0.29-0.48-0.50-0.40-0.40-0.47-0.55-0.52
EPS (Diluted)-0.29-0.48-0.50-0.40-0.40-0.47-0.55-0.52
EBITDA-34.76-47.77-34.59-26.96-27.61-28.31-28.74-27.52
Non-Operating Income (Expense)3.032.461.191.691.801.641.572.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.899.773.022.592.913.032.782.32
Shares Outstanding103.95103.4864.1563.5962.9962.0750.2350.00
Market Capitalization793.34734.40424.84346.09383.90388.15294.32410.60

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments144.24151.09226.17188.83149.0917.4132.47
Short Term Receivables0.000.000.000.000.000.000.00
Inventories0.000.000.000.000.000.000.00
Other Current Assets5.509.535.627.874.621.040.88
Total Current Assets149.74160.62231.79196.70153.7018.4533.35
Net Property, Plant & Equipment18.4520.5922.0026.046.203.573.63
Total Investments and Advances0.770.770.770.770.120.070.07
Intangible Assets----0.000.000.00
Deferred Tax Assets150.55------
Other Assets0.470.520.510.420.000.000.00
Total Assets319.98182.50255.07223.94160.0322.1037.05
Short Term Debt Incl. Current Port. of LT Debt3.243.152.692.960.610.010.00
Accounts Payable1.552.301.792.922.400.612.33
Other Current Liabilities13.599.467.884.574.262.043.82
Total Current Liabilities18.3814.9112.3610.467.272.666.15
Long Term Debt14.1315.6216.8717.890.360.000.05
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities150.55------
Other Liabilities0.000.000.000.000.080.080.10
Total Liabilities183.0630.5329.2328.357.712.746.29
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00128.08118.17
Common Equity136.91151.97225.85195.58152.31-108.71-87.41
Total Shareholders Equity136.91151.97225.85195.58152.3119.3630.76
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity136.91151.97225.85195.58152.3119.3630.76
Total Liabilities & Stockholders Equity319.98182.50255.07223.94160.0322.1037.05
Book Value Per Share2.153.044.585.185.21-3.72-2.99
Tangible Book Value Per Share2.153.044.585.185.21-3.72-2.99
Full-Time Employees113106897052--
Price to Book Ratio2.772.342.232.673.26-3.71-
Return on Assets-42.27-39.73-31.90-30.61-38.71-75.07-
Return on Equity-73.52-46.01-36.26-33.78-41.07-88.60-
Return on Invested Capital-70.30-51.86-31.48-27.53-23.09-114.68-78.54
Quick Ratio8.1510.7718.7618.8121.146.945.42
Current Ratio8.1510.7718.7618.8121.146.945.42

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-136.95-106.19-86.92-76.41-58.76-35.25-22.21-24.20
Depreciation1.061.131.221.291.180.830.830.51
Other Funds (Non Cash)24.4214.358.536.836.092.320.730.56
Funds from Operations-111.47-90.71-77.16-68.29-51.50-32.09-20.64-23.13
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital2.175.97-2.644.44-3.10-0.32-3.682.46
Cash from Operating Activities-109.30-84.74-79.81-63.85-54.60-32.41-24.32-20.67
Capital Expenditures-0.38-0.45-1.25-0.71-1.09-2.12-0.77-2.22
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-140.8236.0470.07-113.25-66.780.000.000.00
Purchase of Investments-269.32-83.96-59.11-233.65-119.780.000.000.00
Sale Or Maturity of Investments128.50120.00129.18120.4053.010.000.000.00
Other Uses0.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-141.2035.5968.82-113.96-67.87-2.12-0.77-2.22
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Change in Capital Stock245.0377.161.5997.2995.63166.2710.0739.76
Repurchase of Common Pref Stock-39.090.000.000.000.000.000.000.00
Sale of Common Pref Stock284.1277.161.5997.2995.63166.2710.0739.76
Proceedsfrom Stock Options283.9476.140.1895.9195.20165.939.9139.71
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00-0.03-0.04
Change in Long Term Debt0.000.000.000.000.000.00-0.03-0.04
Issuance of Long Term Debt0.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00-0.03-0.04
Net Financing Active Other Cash Flow0.000.000.000.000.00-0.010.000.00
Other Financing Activities Uses0.000.000.000.000.00-0.010.000.00
Cash from Financing Activities245.0377.161.5997.2995.63166.2610.0439.73
Exchange Rate Effect-0.41-0.19------
Net Change in Cash-5.8827.82-9.39-80.52-26.84131.72-15.0616.84
Free Cash Flow-109.68-85.19-81.06-64.56-55.70-34.53-25.09-22.89
Preferred Dividends (Cash Flow)-0.000.000.000.00---
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments297.23323.84114.73144.24161.87177.31
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets5.875.193.775.508.256.65
Total Current Assets303.10329.03118.50149.74170.12183.96
Net Property, Plant & Equipment16.5817.1917.8918.4518.8619.49
Total Investments and Advances0.770.770.770.770.770.77
Deferred Tax Assets---150.55--
Other Assets1.171.140.520.470.280.18
Total Assets321.62348.13137.68319.98190.02204.40
Short Term Debt Incl. Current Port. of LT Debt3.323.293.273.243.223.20
Accounts Payable1.722.252.571.551.891.29
Other Current Liabilities16.3014.0110.8713.5913.7110.37
Total Current Liabilities21.3419.5616.7118.3818.8214.85
Long Term Debt12.8513.3013.7214.1314.5314.92
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---150.55--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities34.1932.8630.43183.0633.3629.77
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity287.43315.27107.25136.91156.67174.63
Total Shareholders Equity287.43315.27107.25136.91156.67174.63
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity287.43315.27107.25136.91156.67174.63
Total Liabilities & Stockholders Equity321.62348.13137.68319.98190.02204.40
Book Value Per Share2.773.051.672.152.492.81
Tangible Book Value Per Share2.773.051.672.152.492.81
Full-Time Employees---113--
Price to Book Ratio2.774.253.112.192.202.46
Return on Assets-53.53-47.42-76.70-42.27-53.86-47.97
Return on Equity-61.67-53.49-95.57-73.52-64.26-55.39
Return on Invested Capital-10.68-13.89-27.85-16.92-15.26-14.25
Quick Ratio14.2116.827.098.159.0412.39
Current Ratio14.2116.827.098.159.0412.39

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-32.07-45.64-33.69-25.56-26.13-27.02
Depreciation0.250.260.270.270.280.29
Other Funds (Non Cash)4.7512.473.943.263.743.93
Funds from Operations-27.07-32.91-29.47-22.03-22.11-22.80
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.630.41-0.431.561.962.03
Cash from Operating Activities-26.44-32.50-29.89-20.47-20.14-20.77
Capital Expenditures-0.08-0.02-0.10-0.18-0.04-0.04
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.19-226.0155.0030.00-43.9720.02
Purchase of Investments-13.31-256.010.000.00-73.97-9.98
Sale Or Maturity of Investments13.5030.0055.0030.0030.0030.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.11-226.0354.9029.82-44.0219.98
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.21241.750.302.774.3669.93
Repurchase of Common Pref Stock0.00-39.090.000.000.000.00
Sale of Common Pref Stock0.21280.850.302.774.3669.93
Proceedsfrom Stock Options0.17280.760.242.773.3569.93
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.21241.750.302.774.3669.93
Exchange Rate Effect-0.05-0.17-0.03-0.16-0.01-
Net Change in Cash-26.17-16.9625.2811.96-59.8169.12
Free Cash Flow-26.52-32.52-30.00-20.64-20.19-20.81

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3025.10%10.5M41.7M859.53K
2026-10-1526.11%10.9M41.7M788.50K
2026-09-3015.57%10.4M66.6M732.50K
2026-09-1510.41%7.0M67.8M665.10K
2026-08-319.16%6.2M67.8M650.24K
2026-08-149.00%6.2M68.4M569.24K
2026-07-317.91%6.4M80.4M662.60K
2026-07-158.69%5.6M64.5M654.77K
2026-06-3010.74%6.9M64.6M591.29K
2026-06-158.41%5.4M64.1M515.45K
2026-05-295.82%3.8M64.6M476.05K
2026-05-154.88%3.2M64.6M436.14K
2026-04-304.90%2.2M44.7M269.84K
2026-04-154.50%2.0M44.7M254.69K
2026-03-315.79%2.6M45.2M230.24K
2026-03-135.61%2.5M44.8M212.07K
2026-02-275.03%2.2M44.8M190.15K
2026-02-136.45%2.9M44.8M192.63K
2026-01-306.72%3.2M47.1M194.38K
2026-01-156.78%3.2M47.1M217.21K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.004.509.000.000.0000.000.000.990-0.0130.000
call2.003.508.000.000.0000.000.000.983-0.0130.001
call3.002.507.000.000.0000.000.000.975-0.0130.001
call4.001.506.000.0012.4570.000.000.965-0.0130.001
call5.000.504.900.009.1500.000.000.950-0.0120.001
call6.000.004.900.0010.0800.000.000.931-0.1410.002
call7.000.154.900.2010.7826940.000.864-0.1790.003
call8.000.001.350.002.9880.000.000.640-0.1200.005
call9.000.004.900.003.6380.000.000.510-0.0910.005
call10.000.004.900.004.1420.000.000.479-0.1040.005
call11.000.004.900.004.5620.000.000.457-0.1140.005
call12.000.004.900.004.9220.000.000.441-0.1220.005
call13.000.004.900.005.2370.000.000.428-0.1290.005
call14.000.004.900.005.5170.000.000.418-0.1360.005
put1.000.004.900.007.2120.000.00-0.010-0.0130.000
put2.000.004.900.000.0000.000.000.0000.0000.000
put3.000.004.900.000.0000.000.00-0.035-0.0870.001
put4.000.004.900.000.0000.000.00-0.089-0.1260.002
put5.000.000.050.0029.2260.000.00-0.006-0.0310.000
put6.000.004.900.3016.8523010.00-0.069-0.1400.002
put7.000.004.900.0012.8410.000.00-0.138-0.1750.003
put8.000.004.900.0010.2250.000.00-0.368-0.1130.005
put9.000.004.900.008.2100.000.00-0.490-0.0900.005
put10.000.104.900.006.5970.000.00-0.521-0.1050.005
put11.001.005.500.006.1980.000.00-0.600-0.0940.005
put12.002.006.500.006.5640.000.00-0.619-0.1020.005
put13.003.007.500.006.8870.000.00-0.633-0.1080.005
put14.004.008.500.007.1750.000.00-0.644-0.1130.005

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0910-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-10-27SCHEDULE 13GSEC
2026-10-01SCHEDULE 13GSEC
2026-09-014Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-014Statement of changes in beneficial ownership of securities2026-09-01SEC
2026-09-01S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-20EFFECTEffectiveness filing by commission orderSEC
2026-08-18CORRESPSEC
2026-08-17UPLOADUpload SubmissionSEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13GSEC
2026-08-123Initial statement of beneficial ownership of securities2026-08-10SEC
2026-08-123Initial statement of beneficial ownership of securities2026-08-10SEC
2026-08-123Initial statement of beneficial ownership of securities2026-08-12SEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-11S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-11SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-27SCHEDULE 13G/ASEC
2026-07-084Statement of changes in beneficial ownership of securities2026-07-07SEC
2026-07-083Initial statement of beneficial ownership of securities2026-07-07SEC
2026-07-088-KCurrent report2026-07-03SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-29DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-05SEC
2026-06-17PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-08-05SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060082.33K1
2026-050039.04M1
2026-040082.40K1
2026-030000
2026-0200528.83K5
2026-010089.95K2
2025-120000
2025-110092.73K1

Institutional holders

Manager% owned
TCG Crossover Management, LLC9.22%
MONTANOVA CAPITAL, LLC6.97%
Frazier Life Sciences Management, L.P.6.86%
Nantahala Capital Management, LLC5.71%
Long Focus Capital Management, LLC4.95%
BlackRock, Inc.4.55%
ADAGE CAPITAL PARTNERS GP, L.L.C.4.49%
Caligan Partners LP4.16%
VANGUARD CAPITAL MANAGEMENT LLC3.96%
FCPM III SERVICES B.V.3.92%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.81%
iShares Russell 2000 ETF1.13%
VANGUARD EXTENDED MARKET INDEX FUND1.07%
Franklin Biotechnology Discovery Fund0.74%
Fidelity Small Cap Index Fund0.47%
Fidelity Extended Market Index Fund0.47%
iShares Biotechnology ETF0.44%
iShares Russell 2000 Growth ETF0.38%
VANGUARD HEALTH CARE INDEX FUND0.27%
VANGUARD RUSSELL 2000 INDEX FUND0.25%

OakChart. AURA. Cached 15 minutes.